Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Germany demands that J&J make up COVID-19 vaccine gap in July

06/13/2021 | 05:48am EDT

FRANKFURT, June 13 (Reuters) - Germany's health ministry said Johnson & Johnson must deliver 6.5 million COVID-19 vaccine doses to Germany in July to make up for a shortfall expected in June after the U.S. Food & Drug Administration (FDA) told the company to dispose of millions of doses because of contamination concerns.

"This is regrettable because each dose counts," a ministry spokesman said on Sunday in response to an enquiry by Reuters. "We therefore expect from J&J that this amount is delivered in July as quickly as possible."

Without disclosing or confirming the number of vaccine doses affected, the FDA said in a news release that it had authorised two batches of the vaccine for use, that several other batches were not suitable for use and that others were being evaluated.

A media report citing sources familiar with the matter had said 60 million J&J doses must be discarded, and two sources familiar with the situation told Reuters that about 10 million doses had been cleared by the agency.

The delivery gap hits Germany hard.

J&J had been due to deliver 10.1 million doses of its one-shot vaccine in the second quarter, the ministry said.

The ministry spokesman said that Germany will receive 50.3 million doses of the Pfizer-BioNTech vaccine in the second quarter, Moderna would ship 6.4 million and AstraZeneca 12.4 million, all fulfilling their supply commitments.

(Reporting by Andreas Rinke and Elke Ahlswede Writing by Vera Eckert Editing by David Goodman)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.07% 8274 Delayed Quote.12.89%
MODERNA, INC. -1.98% 346.61 Delayed Quote.238.47%
All news about ASTRAZENECA PLC
11:11aFancy a Covid jab? Here are all the free walk-in sites open in London
AQ
06:32aASTRAZENECA : Saphnelo is a first-in-class type I interferon receptor antibody a..
PU
05:12aASTRAZENECA : H1 2021 results - Roadshow and conferences
PU
04:49aASTRAZENECA : Secures US FDA Approval for Saphnelo in Moderate to Severe Systemi..
MT
04:06aPFIZER : Malawi Ready to Store, Distribute Incoming Covid-19 Vaccine - Official
AQ
02:36aAstraZeneca's Saphnelo Approved in U.S. for Moderate-to-Severe SLE
DJ
02:27aASTRAZENECA : Lupus Therapy Wins US FDA Approval
MT
02:12aASTRAZENECA : Saphnelo (anifrolumab) approved in the US for moderate to severe s..
PU
08/01MARKET CHATTER : Pfizer, Moderna Raise COVID-19 Vaccine Prices in EU Supply Cont..
MT
08/01CORONAVIRUS : Kenya has Received an Additional 410,000 Doses of AstraZeneca The ..
AQ
More news
Financials (USD)
Sales 2021 35 065 M - -
Net income 2021 5 236 M - -
Net Debt 2021 25 946 M - -
P/E ratio 2021 21,9x
Yield 2021 3,41%
Capitalization 128 B 178 B -
EV / Sales 2021 4,40x
EV / Sales 2022 3,56x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 82,74 $
Average target price 133,82 $
Spread / Average Target 61,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC12.89%178 110
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348